The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.

Although the case is considered exceptional, investigators are working to determine how the infection occurred and whether the pathogen played a role in the patient’s death.